Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJan 06, 2026
DataAggregated Company Financials
Companies180
  • 7D0.9%
  • 3M0.6%
  • 1Y-5.1%
  • YTD0.5%

Over the last 7 days, the Pharma industry has remained flat, although notably AstraZeneca Pharma India declined by 5.7%. As for the longer term, the industry has declined 5.1% in the last year. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 07 Jan 2026₹20.5t₹4.2t₹614.8b28.7x33.4x4.9x
Fri, 05 Dec 2025₹20.6t₹4.2t₹612.9b29.2x33.7x4.9x
Sun, 02 Nov 2025₹20.2t₹4.1t₹594.9b29.9x33.9x4.9x
Tue, 30 Sep 2025₹19.8t₹4.1t₹588.1b29.7x33.6x4.9x
Thu, 28 Aug 2025₹20.1t₹4.1t₹589.1b29.8x34.2x5x
Sat, 26 Jul 2025₹20.9t₹4.0t₹595.0b32.8x35.1x5.2x
Mon, 23 Jun 2025₹19.9t₹4.0t₹595.3b31.5x33.5x5x
Wed, 21 May 2025₹19.5t₹4.0t₹582.4b31.5x33.5x4.9x
Fri, 18 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Sun, 16 Mar 2025₹18.5t₹3.9t₹559.4b27x33.2x4.8x
Tue, 11 Feb 2025₹19.8t₹3.9t₹547.6b31.3x36.2x5.1x
Thu, 09 Jan 2025₹21.1t₹3.8t₹527.0b34.5x40.1x5.5x
Sat, 07 Dec 2024₹20.8t₹3.8t₹526.7b36x39.5x5.5x
Mon, 04 Nov 2024₹21.2t₹3.8t₹504.9b38.3x42.1x5.7x
Wed, 02 Oct 2024₹21.6t₹3.7t₹492.6b41.6x43.8x5.8x
Fri, 30 Aug 2024₹20.9t₹3.7t₹492.4b40.4x42.5x5.6x
Sun, 28 Jul 2024₹19.5t₹3.6t₹460.1b36.7x42.4x5.3x
Tue, 25 Jun 2024₹17.4t₹3.6t₹448.3b32.5x38.8x4.9x
Thu, 23 May 2024₹17.2t₹3.5t₹446.5b34.6x38.6x4.9x
Sat, 20 Apr 2024₹16.7t₹3.5t₹418.9b33.1x39.9x4.8x
Mon, 18 Mar 2024₹16.6t₹3.5t₹418.7b31.7x39.7x4.8x
Wed, 14 Feb 2024₹16.7t₹3.4t₹424.5b32.8x39.4x4.9x
Fri, 12 Jan 2024₹15.6t₹3.4t₹396.0b35.4x39.5x4.6x
Sun, 10 Dec 2023₹14.3t₹3.4t₹395.1b31.4x36.1x4.2x
Tue, 07 Nov 2023₹13.2t₹3.3t₹379.0b29.8x34.8x4x
Thu, 05 Oct 2023₹13.3t₹3.3t₹369.5b30x35.9x4.1x
Sat, 02 Sep 2023₹12.8t₹3.3t₹367.0b29.3x34.9x3.9x
Mon, 31 Jul 2023₹12.7t₹3.2t₹345.7b27.7x36.8x4x
Wed, 28 Jun 2023₹11.5t₹3.2t₹342.4b25.8x33.6x3.6x
Fri, 26 May 2023₹10.4t₹3.1t₹297.7b26.3x35.1x3.3x
Sun, 23 Apr 2023₹9.9t₹3.0t₹277.7b26.4x35.8x3.3x
Tue, 21 Mar 2023₹9.3t₹3.0t₹277.5b23.2x33.5x3.1x
Thu, 16 Feb 2023₹9.7t₹3.0t₹277.1b22.9x34.9x3.2x
Sat, 14 Jan 2023₹9.9t₹2.9t₹275.2b26x36.2x3.4x
Price to Earnings Ratio

36.2x


Total Market Cap: ₹9.9tTotal Earnings: ₹275.2bTotal Revenue: ₹2.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 33.4x which is lower than its 3-year average PE of 36.7x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 14% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market1.84%
Healthcare0.95%
Pharma0.86%
Pharma0.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.76k2.3%
+₹96.0b		-5.0%PE40.4x
500420 Torrent Pharmaceuticals₹3.94k3.0%
+₹39.4b		15.7%PE62.3x
MANKIND Mankind Pharma₹2.24k4.1%
+₹36.5b		-23.3%PE52.9x
500257 Lupin₹2.15k3.4%
+₹32.4b		-8.7%PE22.7x
CIPLA Cipla₹1.53k2.6%
+₹30.9b		2.2%PE22.7x

Latest News

524632
₹51.45
Shukra Pharmaceuticals
7D
-17.5%
1Y
195.9%
COHANCE
₹502.30
Cohance Lifesciences
7D
-4.8%
1Y
-54.0%
CIPLA
₹1,530.80
Cipla
7D
2.6%
1Y
2.2%

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
AUROPHARMA
₹1,231.30
Aurobindo Pharma
7D
3.8%
1Y
-5.1%

AUROPHARMA: Margin Optimism Will Face Pressure From Execution And Regulatory Risks

The analyst price target for Aurobindo Pharma has been raised from ₹863 to ₹939 as analysts update their models to reflect modestly higher margin expectations and a slightly richer future earnings multiple despite a marginal trim to long term revenue growth assumptions. Analyst Commentary While the recent price target revision for Aurobindo Pharma reflects greater confidence in margins and earnings quality, not all signals across the broader research landscape are uniformly positive for comparable growth and innovation driven names.
SUNPHARMA
₹1,760.20
Sun Pharmaceutical Industries
7D
2.3%
1Y
-5.0%

SUNPHARMA: ESG Power Shift And Obesity Pipeline Will Drive Bullish Long Term Outlook

Analysts have reiterated their price target on Sun Pharmaceutical Industries at ₹1,950.68 per share, citing broadly unchanged assumptions around discount rates, long term revenue growth, profit margins, and future valuation multiples. What's in the News The U.S. FDA has approved an updated label for Sun Pharma's immunotherapy UNLOXCYT for advanced cutaneous squamous cell carcinoma, incorporating long term pivotal trial data that showed durable responses and no treatment related deaths, with commercial launch targeted for early 2026 (Key Developments).
500420
₹3,936.85
Torrent Pharmaceuticals
7D
3.0%
1Y
15.7%

500420: Patent Settlement And Stable Outlook Will Shape Future Risk Profile

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target on Torrent Pharmaceuticals at ₹4,024. This reflects unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the current fair value assessment.
500124
₹1,255.95
Dr. Reddy's Laboratories
7D
-0.8%
1Y
-7.0%
500257
₹2,151.95
Lupin
7D
3.4%
1Y
-8.7%

500257: Biosimilar And US Regulatory Progress Will Support Balanced Share Performance

Analysts have modestly maintained their conviction on Lupin with the analyst price target effectively unchanged at ₹2,280.84, reflecting stable assumptions on revenue growth, profitability and valuation multiples despite minor model refinements. What's in the News European regulator CHMP issued a positive opinion for Lupin's biosimilar ranibizumab Ranluspec for multiple retinal indications, moving the product closer to centralized EU approval and commercialization via Sandoz and Biogaran in select markets (CHMP, EMA).
524558
₹14,483.50
Neuland Laboratories
7D
-3.2%
1Y
1.4%

524558: New R&D Center Will Drive Future Upside Potential

Narrative Update on Neuland Laboratories Analysts have modestly revised their price target on Neuland Laboratories with a slight adjustment that reflects largely unchanged assumptions around fair value at ₹20,884, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News The board will consider capital expenditure of INR 1,890 million for establishing a new Research and Development Center at the meeting scheduled on November 28, 2025 (Board Meeting).
MANKIND
₹2,240.80
Mankind Pharma
7D
4.1%
1Y
-23.3%

MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating

Narrative Update Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook. What's in the News Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) Valuation Changes Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.
ZYDUSLIFE
₹931.05
Zydus Lifesciences
7D
3.3%
1Y
-7.0%

Is Zydus Lifesciences (NSE:ZYDUSLIFE) Using Too Much Debt?

Nov 29
Is Zydus Lifesciences (NSE:ZYDUSLIFE) Using Too Much Debt?
EMCURE
₹1,528.00
Emcure Pharmaceuticals
7D
9.7%
1Y
7.6%
500488
₹28,429.90
Abbott India
7D
-0.3%
1Y
-5.1%
APLLTD
₹825.70
Alembic Pharmaceuticals
7D
-1.3%
1Y
-24.4%

Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price

Nov 12
Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
506879
₹419.00
Gujarat Themis Biosyn
7D
-3.7%
1Y
26.3%
506820
₹8,395.15
AstraZeneca Pharma India
7D
-5.7%
1Y
18.4%